Will US FDA Offer Regulatory Flexibility For ANDAs Downgraded Because Of CRO Investigation?

Complex generic may have some wiggle room, but the only choice for many sponsors may be to redo the affected studies or withdraw the products that have lost bioequivalence status after FDA questioned the integrity of the data from two contract researchers.

Two doors, two choices
The FDA is offering most sponsors two doors, redoing the BE studies or withdrawing the application, but each has its own challenges. • Source: Alamy

Sponsors with generic products that have been stripped of their bioequivalence ratings because of data integrity problems at two contract research organizations may want regulatory flexibility from the US Food and Drug Administration, but generally appear to have only two choices.

FDA officials have said repeatedly that sponsors can talk with them about options, but for the most part the choices...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

More from Biosimilars & Generics